Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators for neurological disorders. Its modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional ""orthosteric"" small molecules or biological drugs. Its allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.